YMB Your comment has been rejected.

[biopearl123]

What else is new

Hello Wizerdave, you want someone to dispute your facts? Ok then. You contend more patients died on Imetelstat. Actually one patient died in the treatment group and one in the placebo (oh, and there were twice as many patients in the treatment group due to a 2:1 randomization). You contend the CEO sold shares. Everything I’ve seen are sales related to options that came due, either exercise them or lose them. He chose to exercise them as any sane person would. He and the other execs deserve recognition and profit for their work. What else was there? Oh yeah, J and J. They left when they mistakenly failed to realize the importance of prolonging life in MF patients. They did not have much to do or say about the MDS study but probably did look at the data, what 4 years ago in 2018, when they failed to recognize the importance of a new drug that was semi specific in attacking the malignant clone. All J and J did for us (in addition to funding studies) was to enhance to value of our company by walking.. What else? I am really tired of reading your misinformation. Is anyone else? bp

[mistergern]

Count me in BP. Lying seems to be contagious. Hopefully some of us are immune.

[lacour_98]

Me too!

[KTArsenal]

J&J bailed and unknowingly "enhanced the value of Geron by walking" will, for me, go down in imetelchat history as the sickest burn, ever.

Even if that potentially subconscious roast from BP was unintentional, it is gotta be cringe-inducing to their competitors, detractors, and mindless naysayers like Wizerdave and many others.

I raise a full glass to you, BP.

Cheers, mate.

[biopearl123]

Thanks KT, I can assure you it was both conscious and intentional.

[kmall]

While you're on the YMB - this was posted earlier by Josh - good summation of where this stands...

Josh
4h ago


Bullish
I doubt Geron will be around much longer. A much larger pharmaceutical company with deep pockets will scoop this up and start spinning up trials for other indications. Geron played it smart. They refused to let JNJ get all the pie. They did what they had to in order to get an approval as cheaply as possible with the benefit of longer IP protection due to orphan drug designation. Now any company can buy this and immediately start selling Imetelstat while holding the only FDA approved telomerase inhibitor on the market. John Scarlett ( Geron's CEO ) was brought in to get the most money possible. He was not brought in to run some new pharmaceutical company for decades. Geron will be bought out and John Scarlett will retire while everyone else holding shares in Geron gets to walk away with a giant smile on their face.

[Ryan]

Just mute that fool.

[Hoosier Investor]

Simply point out the FDA had all the same data (and more) available for 9+ months of review, and they voluntarily elected to approve the drug on behalf of the LR-MDS patients. Further, the FDA's decision was informed by many subject matter experts.... including those who participated in the ODAC session.

As for the JNJ relationship, there's no doubt that we've benefitted from the partnership. First, they helped design, fund, and execute the P2 trial which highlighted the benefits in the LR-MDS population. Second, the partnership served to inform a significant number of Janssen employees.... several of which decided to follow the drug over to Geron following the discontinuation decision.

As a reminder, JNJ/Janssen had a hard deadline by which they had to make the continuation decision. At the time of the deadline, the survival benefit associated with the MF trial was not known or even anticipated. Janssen was solely evaluating Imetelstat's ability to produce spleen volume reductions (SVRs) in MF patients as had become the standard outcome measure by way of the JAK inhibitors. Further, the relative performance (benefit) of Imetelstat vs. Luspatercept wasn't understood. Luspatercept was the "hot" new drug at the time, and JNJ/Janseen had no choice but to assume Luspatercept was likely to gain approval and subsequently impact (reduce) Imetelstat's commercial value....the full extent to which wasn't understood.

With the benefit of more time, JNJ/Janssen would've likely made a different decision.

At this point, we have a broad approval involving LR-MDS, and we're likely to gain further approvals in R/R MF and AML... within the next 3-5 years. We also have a promising frontline MF combo opportunity, and the company is eyeing & evaluating one (or more) Lymphoma indications. Lastly, thanks to JNJ/Janssen's discontinuation decision, we have 100% ownership of what has/will become a very valuable drug asset & treatment opportunity.

[FC4364]

hear, hear!

[biopearl123]

Well said , HI. Great summary.